Chronic Hepatitis c
Conditions
Brief summary
The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment
Detailed description
Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis C virus (HCV). The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in HCV-infected patients receiving direct-acting antiviral treatment
Interventions
DRUGDirect-acting antiviral therapy
HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* 18 years of age or older * HCV patients treated with direct-acting antiviral treatment * Patients with a prior treatment blood sample * Patients with sustained virological response or virological relapse
Exclusion criteria
* HIV or hepatitis B virus (HBV) coinfection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with positive anti-E1E2 antibody level at treatment initiation | Baseline (treatment initiation day) | Anti-E1E2 antibody levels were determined using optical densities obtained after dilution of patients' serum samples at 1/250 and 1/500. Samples with anti-E1E2 levels above 950 (OD value× 1000) were considered positive |
Countries
France
Outcome results
None listed